Podcast: Ed Nabrotzky, CEO of Industrial Technology Firm Dot Ai
AI assistance is finding its way into an increasing number of corners of the market, and the industrial supply chain is an area that could use help the most. This week, we speak with Ed Nabrotzky, CEO of industrial technology firm Dot Ai. ...READ MORE
Stellar V Capital Corp. (SVCCU) Prices $150M IPO
Stellar V Capital Corp. (NASDAQ:SVCCU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “SVCCU”, Thursday, January 30, 2025. ...READ MORE
Full-Year 2024 SPAC Review
An In-Depth Look at SPAC Activity Throughout the Full-Year of 2024
Below is a summary of the Full-Year 2024 SPAC market. If you’d like a pdf copy, you access the link HERE. ...READ MORE
SPACInsider 2024 Awards and SPAC Deal of the Year
SPACInsider 2024 Awards
2024 was clearly a rebuilding year for SPACs and the pace didn’t really gather momentum until June. But in typical SPAC fashion, once the market catches fire, it builds very, very quickly. ...READ MORE
Translational Development Acquisition Corp. (TDACU) Prices $150M IPO
Translational Development Acquisition Corp. (NASDAQ: TDACU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “TDACU”, Monday, December 23, 2024. ...READ MORE
Range Capital Acquisition Corp. (RANGU) Prices $100M IPO
Range Capital Acquisition Corp. (NASDAQ: RANGU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “RANGU”, Friday, December 20, 2024. ...READ MORE
It Really Does Feel Like 2019 Again…Another Government Shutdown?
SPAC Deja Vu
There’s been a lot of talk this year in the SPAC market about how it’s finally reverting back to a healthier version of deal flow and the comparison is always, “….like ...READ MORE
Podcast: Medera CEO Ronald Li & Keen Vision CEO and Chairman Kenneth Wong
Innovation in gene therapies is hard, but also potentially ground-breaking and biotechnology firm Medera is taking its decades-long journey in the space to the public markets just as hits its next steps in the clinical process. ...READ MORE
